MIAMI – The Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) and PC Trial were both presented last week at TCT 2012 after ...
Patent foramen ovale (PFO) is a normal fetal communication between the right and left atria that persists after birth. PFO is a common finding that occurs in 20–34% of the population, although its ...
It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...
When the CLOSURE I trial results were announced in 2010, many were surprised that percutaneous patent foramen ovale (PFO) closure was not superior to optimal medical therapy for prevention of ...
A retrospective comparison of six patent foramen ovale (PFO) closure devices used in the United States over 18 years shows a trade-off between effectiveness and arrhythmia. Specifically, the ...
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announces positive results from its REDUCE Study assessing closure of patent foramen ovale (PFO) for the reduction of recurrent ...
Two trials presented today at the TCT meeting in Miami testing the benefits of PFO closure in patients with cryptogenic stroke have failed to convincingly demonstrate any significant benefit for the ...
Please provide your email address to receive an email when new articles are posted on . New data from the CLOSE, REDUCE and RESPECT trials demonstrated a lower rate of recurrent ischemic stroke after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback